source
- Biopharma M&A stays robust as companies shift focus from megadeals to smaller targetsThe article notes that despite a slowdown in large megadeals, overall merger and acquisition activity in the biopharma sector remains strong. Companies are adopting multi‑pronged strategies to add…
- Amgen tightens 340B program rules, expanding pharmacy claims data requirementsAmgen announced it is expanding the data it requires from pharmacies that dispense its products under the federal 340B drug discount program. The new policy will obligate participating pharmacies…